Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down

By Zacks Investment ResearchStock MarketsMar 11, 2019 10:58PM ET
Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down
By Zacks Investment Research   |  Mar 11, 2019 10:58PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Avanos Medical, Inc. (NYSE:AVNS) reported adjusted earnings of 30 cents per share in fourth-quarter 2018, which surpassed the Zacks Consensus Estimate of 24 cents. However, the metric plunged 58.9% year over year.

For 2019, the company expects adjusted earnings between $1.15 and $1.35 per share. The mid-point of $1.25 is below the Zacks Consensus Estimate of $1.29. Following the earnings announcement, shares of this Zacks Rank #4 (Sell) company decreased 14.6%, to close at $43.12 on Mar 11.

Revenues totaled $169.9 million, which missed the Zacks Consensus Estimate of $166 million but increased 2.2% on a year-over-year basis.

AVANOS MEDICAL, INC. Price and Consensus

2018 at a Glance

Net revenues in 2018 amounted to $652.3 million, up 6.7% on a year-over-year basis.

Chronic Care revenues were $386 million, up 7% year over year. The segment accounted for 59.2% of net revenues.

Pain Management revenues were $266.3 million, up 6.2% year over year. The segment accounted for 40.8% of net revenues.

Q4 Segmental Analysis

Chronic Care

Net revenues at this segment summed $98.2 million, up 3.7% year over year. However, distributors within Chronic Care held an elevated level of inventory in the Digestive Health product unit by the end of the fourth quarter.

Pain Management

The segment posted net revenues of $71.7 million. The metric inched up 0.1% on a year-over-year basis.

Margin Analysis

Adjusted gross profit came in at $102.7 million, up 13% from the prior-year quarter figure. Adjusted gross margin was 60.4% of net revenues, up 570 basis points (bps) year over year.

Research and development expenses totaled $10.6 million, down 12.4% year over year. Selling, general and administrative expenses amounted to $87.9 million, up 13.6% year over year.

Adjusted operating profit in the fourth quarter was $20 million, skyrocketing 203% on a year-over-year basis. Adjusted operating margin in the quarter was 11.8% of net revenues, up from 4% in the year-ago quarter.


Avanos expects 2019 net revenues to increase 6-8% year over year, on a constant-currency basis (including Game Ready). Overall, the company expects savings in the range of $7-$10 million for 2019. With the establishment of the IT infrastructure, the company projects additional savings of $14-$18 million in 2020.

Avanos expects Chronic Care segment to grow in mid-single digits. The company also expects to launch multiple new products in the segment to maintain its leading share position.

The company also plans to invest in its market-leading CORTRAK tube-tracking technology to establish it as the standard of care for bed-side placement of small-bore nasoenteric feeding tubes.

During the first half of 2019, Avanos expects six-month results from the hyaluronic acid study and the health economic study.

In 2019, Avanos plans to make huge investments (most of which will happen during the first half of the year). During the first quarter, the company is expected to expand its COOLIEF direct-to-patient television advertising into new markets. Overall, its investments for the first half of 2019 are expected to exceed investments in the second half of the year.

Earnings of MedTech Majors at a Glance

Some better-ranked MedTech stocks that delivered solid results in the respective quarters are Varian Medical Systems (NYSE:VAR) , AngioDynamics (NASDAQ:ANGO) and CONMED Corporation (NASDAQ:CNMD) .

Varian reported first-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2 (Buy).

AngioDynamics’ second-quarter fiscal 2019 adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

CONMED delivered fourth-quarter 2018 adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million outshined the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>

Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report

AngioDynamics, Inc. (ANGO): Free Stock Analysis Report

CONMED Corporation (CNMD): Free Stock Analysis Report

AVANOS MEDICAL, INC. (AVNS): Free Stock Analysis Report

Original post

Zacks Investment Research
Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down

Related Articles

Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email